摘要
抗体靶向型细胞质的药物是难以实现抗原抗体相互作用,导致负载被定向到小隔间。然而,由于F-protein介导膜融合,仙台病毒包膜会引起细胞质传递。本研究中我们已经生成并融合重组scFv定向到肿瘤-胎儿抗原,是一种具有膜转运和仙台F蛋白的部分胞质域的胎盘碱性磷酸酶同工酶(PAP)。重组病毒颗粒,同时拥有融合蛋白以及主体F-蛋白,能够具体绑定和释放药物至PAP表达细胞。大约75%的递质是胞质。因此,这免疫病毒颗粒缺乏相对毒性更大的HN蛋白,能够结合具体抗体介导的胞质递质。scFv能特异性结合PAP表达细胞,没有与其他碱性磷酸酶同功酶的交叉反应。胞质传递的优势包括减少低负载和载体的免疫原性的退化和削弱。PAP在各种癌症如精原细胞瘤、绒毛膜癌,宫颈癌和乳腺癌等中的表达普遍存在,也表明其在众多恶性肿瘤治疗中的潜在作用。
关键词: F-蛋白,F-病毒颗粒,胎盘碱性磷酸酶,单链抗体可变区基因片段,仙台病毒,靶向给药
Current Molecular Medicine
Title:Membrane Fusion Mediated Targeted Cytosolic Drug Delivery Through scFv Engineered Sendai Viral Envelopes
Volume: 15 Issue: 4
Author(s): M. Kumar, P. Mani, P. Pratheesh, S. Chandra, M. Jeyakkodi, P. Chattopadhyay, D.P. Sarkar and S. Sinha
Affiliation:
关键词: F-蛋白,F-病毒颗粒,胎盘碱性磷酸酶,单链抗体可变区基因片段,仙台病毒,靶向给药
摘要: Antibody targeted cytoplasmic delivery of drugs is difficult to achieve as antigen-antibody interaction results in the payload being directed to the endosomal compartment. However, Sendai viral envelopes can bring about cytoplasmic delivery due to F-protein mediated membrane fusion. In this study we have generated and fused a recombinant scFv directed to the onco-fetal antigen, the Placental isozyme of Alkaline Phosphatase (PAP) with the trans-membrane and part of the cytoplasmic domain of the Sendai F protein (FTMC). Reconstituted virosomes, having both the fusion protein as well as the native F-protein were able to specifically bind and deliver drugs to PAP expressing cells. About 75% of the delivery was cytoplasmic in nature. Hence, this immuno-virosome, which is devoid of the comparatively more toxic HN protein, has the novel ability to combine specific antibody mediated targeting with cytoplasmic delivery. The scFv ensured specific binding to PAP expressing cells, without cross reacting with the other isozymes of alkaline phosphatase. The advantages of cytoplasmic delivery would include reduced degradation and lowered immunogenicity of the payload and carrier. The ubiquitous expression of PAP on a variety of cancers like seminoma, choriocarcinoma, cervical and breast cancers also suggests its potential usefulness in a number of malignancies.
Export Options
About this article
Cite this article as:
M. Kumar, P. Mani, P. Pratheesh, S. Chandra, M. Jeyakkodi, P. Chattopadhyay, D.P. Sarkar and S. Sinha , Membrane Fusion Mediated Targeted Cytosolic Drug Delivery Through scFv Engineered Sendai Viral Envelopes, Current Molecular Medicine 2015; 15 (4) . https://dx.doi.org/10.2174/1566524015666150505155949
DOI https://dx.doi.org/10.2174/1566524015666150505155949 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Placental Growth Hormone, Fetal Growth and the IGF Axis in Normal and Diabetic Pregnancy
Current Diabetes Reviews Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design Reconstituted High Density Lipoprotein-Based Nanoparticles: an Overview of Applications in Regenerative Medicine, Preparation, Evaluation and Future Trends
Current Pharmaceutical Design Drug Targeting Approaches and Use of Drug Delivery Systems in Management of Cancer
Current Pharmaceutical Design (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) Mammalian Nucleoside Transporters
Current Drug Metabolism An overview of ABC and SLC Drug Transporter Gene Regulation
Current Drug Metabolism Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Kisspeptin: Paving the Way to a New Therapeutic Avenue in Reproduction
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Patent Analysis as a Tool for Research Planning: Study on Natural Based Therapeutics Against Cancer Stem Cells
Recent Patents on Anti-Cancer Drug Discovery Heat Shock Factor 1-Regulated miRNAs Can Target Huntingtin and Suppress Aggregates of Mutant Huntingtin
MicroRNA Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Current Pharmaceutical Design Search for New and Novel Chemotherapeutics for the Treatment of Human Malignancies
Mini-Reviews in Medicinal Chemistry Placental Transport of Folate and Thiamine: A Mini-Review
Current Women`s Health Reviews Folate Receptor Targeted Liposomes
Drug Design Reviews - Online (Discontinued) Galanthus nivalis Agglutinin (GNA)-Related Lectins: Traditional Proteins, Burgeoning Drugs?
Current Chemical Biology Iron Oxide Nanoparticles: An Insight into their Biomedical Applications
Current Medicinal Chemistry Overview of Mechanisms of Cancer Stem Cell Drug Resistance
Current Signal Transduction Therapy Blockade of Neoangiogenesis, a New and Promising Technique to Control the Growth of Malignant Tumors and their Metastases
Current Vascular Pharmacology Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Chemosensitization by Antisense Oligonucleotides Targeting MDM2
Current Cancer Drug Targets